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Abstract
Introduction: There is no single blood marker for predicting the prognosis in ischemic stroke. A combination of
multiple blood markers may enhance the ability to predict long-term outcome following ischemic stroke.
Methods: Blood concentrations of neuronal markers (neuron-specific enolase, visinin-like protein 1, heart type fatty
acid binding protein (hFABP) and neuroglobin), astroglial markers (S100B and glial fibrillary acidic protein),
inflammatory markers (IL-6, TNF-a, and C-reactive protein), blood-brain barrier marker (matrix metalloproteinase 9),
and haemostatic markers (D-dimer and PAI-1) were measured within 24 hours after stroke onset. The discrimination
and reclassification for favorable and poor outcome were compared after adding individual or a combination of
blood markers to the clinical model of stroke outcome.
Results: In multivariate analysis, natural log-transformed (log) IL-6 (odds ratio (OR): 1.75, 95% CI: 1.25 to 2.25, P =
0.001) and loghFABP (OR: 3.23, 95% CI: 1.44 to 7.27, P = 0.005) were independently associated with poor outcome.
The addition of a single blood marker to the clinical model did not improve the discriminating ability of the
clinical model of stroke outcome. However, the addition of the combination of logIL-6 and loghFABP to the clinical
model showed improved discrimination (area under receiver operating characteristic (AUROC) curve: 0.939 versus
0.910, P = 0.03) and reclassification performance (net reclassification improvement index: 0.18, P = 0.005).
Conclusions: A combination of circulating IL-6 and hFABP level has an additive clinical value for the prediction of
stroke outcome.
Introduction
The early prediction of long-term clinical outcome fol-
lowing ischemic stroke is important because of the high
morbidity and mortality associated with stroke. Intrave-
nous tissue plasminogen activator (tPA) is the only effec-
tive treatment for ischemic stroke, but less than 15% of
all patients are eligible for thrombolytic therapy due to
its narrow therapeutic window [1]. In patients who were
not indicated for thrombolytic therapy, early initiation of
treatment to reduce secondary neuronal damage is
required for a favorable outcome. Age and initial clinical
severity, represented by the National Institutes of Health
Stroke Scale (NIHSS) score, are established clinical pre-
dictors for long-term outcome [2]. Brain imaging is a
powerful diagnostic tool to determine the extent of neu-
ronal injury which is associated with long-term stroke
outcome. However, brain imaging has several limitations
with regard to feasibility and cost-effectiveness.
Blood biomarkers can be a complementary tool for
diagnosis [3], predicting prognosis [4,5] and therapeutic
monitoring of novel treatments in ischemic stroke [6].
Blood markers of neuronal injury, astroglial injury,
inflammatory mediators, and/or thrombotic/haemostatic
proteins are candidate blood markers for early stroke
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recurrence or long-term clinical outcome in previous
case-control studies [7-11]. For the clinical application of
biomarkers for stroke prognosis, candidate blood mar-
kers must satisfy the proposed criteria for an ideal blood
marker [4,12]; 1) the marker has a statistically indepen-
dent association with outcome after adjusting for clinical
covariates; 2) the marker improves the discriminating
ability of the established clinical model; and 3) the mar-
ker can reclassify patients at low or high risk for poor
outcome across clinically relevant thresholds of predicted
probabilities of stroke outcome.
Although many blood markers have been investigated
to date, no single blood marker has been proven to be
clinically useful to predict stroke outcome [12]. The rea-
son is that most of the previous studies measured a sin-
gle blood marker in a case-control design with variable
time points of sampling. Profiling studies of multiple
markers, the mechanisms of which are differentially
associated with stroke pathophysiology, have tried to
overcome the limitation of a single biomarker for stroke
diagnosis [13] or outcome [4,5,10]. Several panels of
inflammatory and haemostatic markers, such as IL-6,
N-terminal pro-brain natriuretic peptide, C-reactive pro-
tein (CRP), fibrinogen, and/or D-dimer, have been sug-
gested to be associated with poor clinical outcome and
death [4,5,10]. However, whether the addition of blood
biomarkers improves the predictability of the clinical
predictors for stroke outcome remains controversial
[4,5,10]. Therefore, clinically applicable panels of blood
markers should be evaluated in subsequent studies.
The aim of the present study is to measure the blood
concentration of multiple blood markers in stroke patients
and investigate the clinically available blood markers for
prediction of the long-term clinical outcome.
Materials and methods
Study subjects
We received informed consent from all patients or their
families, and the Institutional Review Board at CHA
Bundang Medical Center approved the study protocol
(IRB protocol no: 2008-034). Among the 353 patients
with clinical presentation of stroke who were admitted
to the CHA Bundang Medical Center between January
2009 and June 2010, we included only patients who met
the following inclusion criteria: (1) symptom onset
between 6 and 24 hours prior to blood sampling, (2)
first-ever-stroke without any previous history of neuro-
logical disease, (3) adequate access to patient’s informa-
tion, and (4) agreement to participate in the study
protocol. We excluded patients with (1) intravenous or
intra-arterial thrombolytic therapy (n = 26), (2) interven-
tional treatment (n = 6), (3) neurological symptoms that
resolved within 24 hours (n = 21), (4) history of malig-
nancy (n = 11), (5) evidence of acute systemic infection
(for example, fever, pneumonia, urinary tract infection)
at the time of blood sampling (n = 8), (6) cerebral
hemorrhage and head trauma (n = 14), or (7) refusal to
participate in the study protocol (n = 83). Among the
184 patients, 9 patients were later excluded because the
blood samples showed poor quality or hemolysis during
preparation and were discarded. Therefore, a total of
175 cases were included in the multiple blood marker
study (age, 66 ± 11 years, 54% male).
Assessment of clinical parameters
Ischemic stroke is defined as a clinically definite stroke
in a patient whose brain imaging shows a positive lesion
on brain magnetic resonance imaging (MRI) or vascular
insufficiency relevant to clinical symptoms. At 72 hours
after the stroke, all of the patients underwent diffusion
weighed imaging (DWI) of the brain MRI to examine
the presence of acute infarction. Additional cerebral
angiography (one or combined computed tomography
(CT)-, MR and/or conventional cerebral angiography)
was performed to detect vascular occlusion in all of the
patients during hospitalization. All stroke patients
underwent electrocardiography and cardiac enzyme (tro-
ponin and CK-MB) evaluation at admission, and none
had evidence of concurrent acute coronary syndrome.
Additional cardiac tests included trans-thoracic echocar-
diogram (95%), trans-esophageal echocardiogram (74%),
and 24-hour electrocardiogram monitoring (77%).
Vascular risk factors were determined as positive past
history, current treatment and positive laboratory find-
ings, including systolic and diastolic blood pressure (SBP
and DBP), blood tests for fasting glucose, creatinine, and
lipid profile. Hypertension was defined as a high base-
line blood pressure (systolic ≥ 140 mm Hg or diastolic ≥
90 mm Hg) or a history of antihypertensive medication.
Diabetes mellitus (DM) was defined as fasting plasma
glucose of ≥ 126 mg/dL or a history of insulin or oral
hypoglycemic therapy. Smoking was defined as current
smokers at the time of examination. Hyperlipidemia was
defined as fasting serum total cholesterol of ≥ 220 mg/dL
or a history of treatment with a statin. Cardiac disease
included a previous history or evidence of valvular heart
disease, ischemic heart disease, atrial fibrillation (Afib)
and heart failure. All of the stroke patients underwent
standardized neurological examination by experienced
neurologists during hospitalization. Neurological severity
was quantified using NIHSS scores from admission to
discharge. Long-term clinical outcome was determined
by the use of a modified Rankin scale score at three
months (3m-mRS) after symptom onset by the same neu-
rologists who were blinded to laboratory results. The
favorable outcome group was defined as patients with
3m-mRS scores of 0 to 2 (n = 111), and the poor out-
come group was defined as patients with 3m-mRS scores
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≥ 3 (n = 64). The mechanism of stroke was evaluated
according to Trial of Org10172 in Acute Stroke Treat-
ment (TOAST) criteria [14].
Measurement of plasma concentration of biomarkers and
infarct volume
Whole blood (10cc) was drawn on arrival at the emer-
gency department using a tube containing ethylenedia-
minetetraacetic acid (EDTA) or citrate. The samples
were immediately delivered to the laboratory. Plasma
and serum were quickly isolated from whole blood via
centrifuge (3,000 g for 15 minutes), and the samples
were stored at -80°C for later analysis. In laboratories
blinded to clinical information, a total of 12 panel mar-
kers, including: (1) neuronal markers: neuron-specific
enolase (NSE), neuroglobin (Ngb), heart-type fatty acid
binding protein (hFABP) and visinin-like protein 1
(VSNL-1); (2) astroglial markers: S100B and glial fibril-
lary acidic protein (GFAP); (3) inflammatory markers:
C-reactive protein (CRP), IL-6 and TNF-a; (4) blood-
brain barrier marker: matrix metalloproteinase-9 (MMP-
9); and (5) haemostatic markers: D-dimer and plasmino-
gen activator inhibitor-1 (PAI-1), were measured using
commercially available ELISA kits according to the
manufacturer’s protocols. We selected blood markers
that were plausibly associated with the pathophysiology
of ischemic stroke, based on previous experimental and
clinical studies. Detailed methods for the measurement
of individual blood markers are described in Additional
file 1.
Infarct volume was assessed using 72-hour DWI of
hyperintense lesions. The infarct size at each slice was
initially measured using a semi-computerized, intensity-
threshold technique (Image J software, NIH, Bethesda,
MA, USA). The infarct volume was calculated as the
infarct size multiplied by the inter-slice thickness (6 mm),
and the total infarct volume was determined by summat-
ing the infarct volumes at each slice.
Statistical analysis
The categorical data (sex and presence of vascular risk
factors) were compared between two groups using the
c2 test. Continuous data (age, SBP, DBP, routine labora-
tory data, and blood markers) were compared between
two groups using the Student’s t-test or a Mann-Whitney
U test if the variables were not matched to a standard
normal distribution. All tested blood markers showed
highly skewed data (Kolmogorov-Smirov test < 0.02) and
were natural log-transformed (+1 if zero value is present).
As most stroke patients showed negative GFAP (71.4%)
and VSNL-1 (93.1%) in the peripheral blood at this time
point, these markers are regarded as binary variables
(positive or negative). Data of continuous variables were
expressed as mean ± standard deviation or median with
IQR. The relationship between blood markers and infarct
volume was evaluated with Spearman’s correlation coeffi-
cient test.
For independent association between individual blood
markers and stroke outcome, each natural log-transformed
(log) blood marker was entered into a separate model after
adjusting for age and initial NIHSS score. We constructed
a baseline clinical model including age and initial NIHSS
score for stroke outcome using logistic regression analyses
[15]. Age and initial NIHSS score showed a strong associa-
tion with stroke outcome after adjusting for other clinical
covariates, such as vascular risk factors, Afib and white
blood cell (WBC) count in multivariate analysis (P < 0.01).
Vascular risk factors, Afib and WBC count were not statis-
tically significant after adjusting for age and initial NIHSS
score (all P > 0.05). Although infarct volume and TOAST
subtype were associated with stroke outcome, we excluded
these variables as clinical covariates because: 1) these vari-
ables could not be obtained within 24 hours after stroke
onset; 2) multi-collinearity was suspected between infarct
volume and NIHSS score (r = 0.65, P < 0.0001); and (3) the
statistical power of these variables was weaker than
the NIHSS score for prediction of stroke outcome. A
P value of < 0.005 for each blood marker was regarded as
significant for multiple comparison hypotheses (compari-
son of 12 blood markers in this study).
To examine whether the addition of blood markers
improved the predictability of the baseline clinical model
for stroke outcome, we conducted multivariate logistic
regression analysis by entering individual or a combined
set of log IL-6 and log hFABP into the baseline clinical
model. The changes of -2log likelihood ratio and Hosmer-
Lemeshow’s model were compared among the models.
The ability of the model to discriminate between favorable
and poor outcome was assessed by receiver operating
characteristic (ROC) curve analysis in each model. The
differences in area under the curve (AUC) between
the blood marker model and baseline clinical model were
tested using the Delong method with regard to whether
the addition of individual or combined blood markers
improved the discrimination between the favorable and
poor outcome groups. Additionally, we calculated the net
reclassification improvement (NRI) index and integrated
discrimination index (IDI) with the clinically relevant
thresholds of the predicted probability of baseline clinical
model as proposed by a previous study [4]: 0.10 (very low
risk), 0.50 (intermediate risk), and 0.90 (very high risk).
We determined these thresholds because we examined
whether the addition of blood markers can reclassify the
very low-risk and very high-risk groups for poor outcome
who need conservative care or aggressive treatment.
Values less than 0.05 were considered significant associa-
tions. The statistical analyses were performed using SPSS
version 18.0 (SPSS, Chicago, IL, USA), MedCalc version
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11.3 (Mariakerke, Belgium), and the R package for
Windows (version 2.12.2).
Results
The demographic and laboratory characteristics between
the favorable and poor outcome groups are described in
Table 1. The poor outcome group was older, had a
higher WBC count and had a higher prevalence of Afib
than the favorable outcome group. The poor outcome
group had a higher median initial NIHSS score and lar-
ger median DWI volume than the favorable outcome
group. The univariate logistic regression model indicates
that age (OR: 1.58 (per 10 years), 95% CI: 1.17 to 2.12,
P = 0.002), initial NIHSS score (OR: 4.20 (per 3 points),
95% CI: 2.70 to 6.52, P < 0.001), Afib (OR: 4.29, 95% CI:
2.17 to 8.48, P < 0.001) and WBC count (adjusted OR:
1.11 (per 103/μl), 95% CI: 1.03 to 1.19, P = 0.005) were
associated with poor prognosis. TOAST classification,
especially small vessel disease subtype and small infarct
volume were associated with favorable outcome (P < 0.01).
In the multivariate analysis of clinical variables, only age
and initial NIHSS showed a strong association with poor
stroke outcome (all P < 0.01), with the disappearance of
significance for Afib and WBC count (P > 0.05). Among
nine deceased patients (3m-mRS = 6), six died from the
stroke itself (three large hemispheric stroke, two basilar
stroke, and one cerebral hemorrhage), and three likely
died from non-stroke causes (two cardiopulmonary dis-
tress, one sepsis).
The median concentrations of individual blood mar-
kers are shown in Table 2. The median sampling time
after stroke onset was 10 hours (IQR: 7 to 16). The
poor outcome group had higher median blood concen-
trations of hFABP, S100B, IL-6, MMP-9, CRP, and
D-dimer than the favorable outcome group. The blood
concentrations of NSE, TNF-a and PAI-1 were not dif-
ferent between the two groups. As described above,
most of the stroke patients displayed negative GFAP
and VSNL-1 in the peripheral blood during this time
period, indicating that these proteins are unlikely to be
released from the brain to the bloodstream during this
time window of stroke.
The logistic regression analysis of individual blood
markers after adjusting for age and initial NIHSS score
revealed that plasma logIL-6 (adjusted OR: 1.75, 95% CI:
1.25 to 2.25, P = 0.001) and loghFABP (adjusted OR:
3.23, 95% CI: 1.44 to 7.27, P = 0.0045) reached a statisti-
cal significance (Table 3). The statistical significance of








Age (years old) 66 ± 11 64 ± 11 69 ± 10 0.002
Sex (male, %) 95 (54.3) 56 (50.5) 39 (60.9) 0.21
Initial NIHSS score 5 (3 to 10) 4 (2 to 5) 12 (7 to 16) < 0.001a
72 hour-infarct volume (ml)b 5.9 (1.4 to 35.0) 3 (1 to 9) 55 (5 to 215) < 0.001a
Sampling time (hours) 10 (7 to 16) 10 (7 to 17) 11 (8 to 15) 0.66a
Hypertension (%) 101 (57.7) 61 (55.0) 40 (62.5) 0.35
Diabetes mellitus (%) 53 (30.3) 36 (32.4) 17 (26.6) 0.50
Hyperlipidemia (%) 42 (24.0) 26 (23.4) 16 (25.0) 0.81
Heart failure (%) 17 (9.7) 8 (7.2) 9 (14.1) 0.19
Atrial fibrillation (%) 53 (30.3) 21 (18.9) 32 (50.0) < 0.001
Smoking (%) 71 (40.6) 47 (42.3) 24 (37.5) 0.63
Previous statin use (%) 26 (14.9) 17 (15.3) 9 (14.1) 0.99
Systolic BP (mmHg) 134 ± 19 134 ± 19 133 ± 18 0.68
Diastolic BP (mmHg) 82 ± 12 81 ± 10 83 ± 14 0.21
Creatinine (mg/dl) 1.07 ± 0.56 1.04 ± 0.62 1.11 ± 0.42 0.46
Fasting glucose (mg/dl) 138 ± 55 135 ± 57 143 ± 53 0.37
LDL cholesterol (mg/dl) 115 ± 37 118 ± 29 109 ± 47 0.17
WBC (103/μl) 7.8 ± 3.0 7.7 ± 2.7 9.2 ± 3.7 < 0.01
TOAST < 0.01
LAA 52 (29.7) 35 (31.5) 17 (26.6)
CE 49 (28.0) 25 (22.5) 24 (37.5)
SVD 38 (21.7) 34 (30.6) 4 (6.3)
Others 36 (20.6) 17 (15.3) 19 (29.7)
aStatistical analysis conducted using the Mann-Whitney U test; bhyperintense lesion on diffusion-weighted image 72 hours after stroke. BP, blood pressure; CE,
cardioembolism; LAA, large-artery atherosclerosis; LDL, low density lipoprotein cholesterol; NIHSS, National Institutes of Health Stroke Scale; SVD, small vessel
disease; TOAST, Trial of Org10172 in the Acute Stroke Treatment; WBC, white blood cell.
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logIL-6 and loghFABP remained after further adjustment
for 72-hour infarct volume (natural log-transformed)
and Afib (logIL-6, OR: 1.74, 95% CI: 1.24 to 2.44, P =
0.003; loghFABP, OR: 3.23, 95% CI: 1.41 to 7.40, P =
0.001), time of stroke onset (logIL-6, OR: 1.74, 95%
CI: 1.24 to 2.44, P = 0.001; loghFABP, OR: 3.23, 95%
CI: 1.41 to 7.40, P = 0.005) and previous statin use
(logIL-6, OR: 1.81, 95% CI: 1.27 to 2.57, P = 0.001; logh-
FABP, OR: 3.36, 95% CI: 1.46 to 7.47, P = 0.004). Add-
ing the logIL-6 and loghFABP to the baseline clinical
model improved the -2 log likelihood ratio (102.57 versus
123.01, P = 0.01) and goodness of fit (Hosmer-Lemeshow’s
test, P = 0.506). No multi-collinearity was found among
the tested variables. In the Spearmann’s correlation









NSE (ng/ml) 6.5 (1.9 to 10.8) 5.6 (1.6 to 10.3) 7.7 (3.0 to 11.5) 0.14
Ngb (ng/ml) 0.0 (0.0 to 2.7) 0.0 (0.0 to 0.9) 0.3 (0.0 to 9.7) < 0.001
hFABP (ng/ml) 10.0 (6.2 to 16.3) 8.4 (5.5 to 11.9) 16.3 (9.9 to 29.7) < 0.001
VSNL-1 (%)b 12 (6.9) 7 (6.3) 5 (7.8) 0.95
Astroglial
S100B (pg/ml) 31.9 (0.0 - 124.9) 20.0 (0 to 60.3) 135.2 (40.0 to 344.6) < 0.001
GFAP (%)b 50 (28.6) 23 (20.7) 27 (42.2) 0.004
Inflammatory
IL-6 (pg/ml) 4.6 (0.9 to 13.0) 2.2 (0.6 to 5.5) 12.1 (6.7 to 48.0) < 0.001
MMP-9 (ng/ml) 65.4 (30.9 to 124.1) 45.7 (21.9 to 79.5) 120.5 (61.8 to 228.3) < 0.001
TNF-a (pg/ml) 2.3 (0.0 to 8.9) 1.3 (0.0 to 8.0) 3.3 (0.0 to 10.4) 0.22
CRP (mg/dl) 0.26 (0.09 to 0.94) 0.19 (0.06 to 0.36) 0.87 (0.18 to 4.40) < 0.001
Haemostatic
PAI-1 (ng/ml) 11.1 (4.5 to 21.8) 10.3 (4.2 to 23.1) 11.5 (5.9 to 20.9) 0.57
D-dimer (ng/ml) 521 (368 to 1083) 466 (355 to 933) 938 (450 to 1629) 0.001
aStatistical analysis conducted by the Mann-Whitney U test; bCategorical variables. Values in round brackets indicate interquartile range. CRP, C-reactive protein;
GFAP, glial fibrillary acidic protein; hFABP, heart type fatty acid binding protein; MMP-9 matrix metalloproteinase-9; Ngb, neuroglobin; NSE, neuron-specific
enolase; PAI-1, plasminogen activator inhibitor-1; VSNL-1, visinin-like protein 1.
Table 3 Multivariate logistic regression analysis of blood markers (natural log-transformed) between favorable and
poor outcome groups
OR (95% CI) P Adjusted ORa P
Neuronal markers
NSE 1.23 (0.89 - 1.68) 0.209 0.79 (0.49 - 1.26) 0.325
Ngb 1.73 (1.28 - 2.34) 0.0004 1.41 (0.89 - 2.24) 0.143
hFABP 4.90 (2.67 - 9.00) < 0.0001 3.23 (1.44 - 7.27) 0.0045
VSNL-1b 1.26 (0.38 - 4.14) 0.704 0.87 (0.19 - 4.02) 0.854
Astroglial markers
S100B 1.60 (1.39 - 1.92) < 0.0001 1.20 (0.96 - 1.51) 0.115
GFAPb 2.79 (1.42 - 5.49) 0.003 1.15 (0.41 - 3.22) 0.791
Inflammatory markers
IL-6 2.23 (1.68 - 2.95) < 0.0001 1.75 (1.25 - 2.25) 0.001
TNF-a 1.22 (0.94 - 1.57) 0.134 1.35 (0.88 - 2.05) 0.166
CRP 1.63 (1.33 - 1.99) < 0.0001 1.23 (0.94 - 1.62) 0.148
Blood-brain barrier marker
MMP-9 2.19 (1.43 - 3.44) 0.005 1.65 (1.07 - 2.07) 0.014
Haemostatic markers
PAI-1 1.05 (0.79 - 1.38) 0.748 1.07 (0.71 - 1.61) 0.751
D-dimer 2.49 (1.61 - 3.86) < 0.0001 1.37 (0.74 - 2.57) 0.319
The favorable group is regarded as the reference (OR: 1.0). aAdjustment of age and initial NIHSS score; bcategorical variables. CI, confidence interval; CRP, C-
reactive protein; GFAP, glial fibrillary acidic protein; hFABP, heart type fatty acid binding protein; MMP-9 matrix metalloproteinase-9; Ngb, neuroglobin; NSE,
neuron-specific enolase; OR, odds ratio; PAI-1, plasminogen activator inhibitor-1; VSNL-1, visinin-like protein 1.
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analysis, infarct volume was significantly correlated with
IL-6 (r = 0.38, P < 0.001) but not hFABP (r = 0.126, P =
0.10).
In ROC curve analysis, the baseline clinical model
showed good discriminating ability (AUC: 0.910) for
stroke outcome. The addition of any single marker did
not significantly improve the AUC value of the baseline
clinical model. Adding a combination of logIL-6 and
loghFABP to the baseline clinical model (AUC: 0.939,
P < 0.03) significantly improved the discriminating abil-
ity of the baseline clinical model (Table 4 and Figure 1).
The addition of other individual markers to the com-
bined model of logIL-6, loghFABP and clinical model did
not result in further improvement of AUC in ROC
curve analysis (P ≥ 0.05 by the DeLong method). We
further calculated the in-sample NRI index and IDI of
logIL-6 and loghFABP in each model (Table 4). Adding
logIL-6 to the baseline clinical model significantly
improved the NRI index (0.09, P = 0.04) but adding
loghFABP to the baseline clinical model did not improve
the NRI index. The addition of both logIL-6 and logh-
FABP further enhanced the NRI index of logIL-6 (0.18,
P = 0.005). The in-sample reclassification table in the
model with logIL-6 and loghFABP is presented in Addi-
tional file 2. In 64 patients with a poor outcome, seven
were reclassified into higher risk categories, and only
two were reclassified into lower risk categories. In 111
patients with a favorable outcome, only six were reclas-
sified into higher risk categories, and 17 were reclassi-
fied into lower risk categories.
Discussion
In the present study, we measured multiple blood markers
that are plausibly related to the pathophysiology of ischemic
stroke to predict functional outcome. The strengths of the
present study include the prospective collection of stroke
cases, measurement of multiple blood markers in a single
study, exact diagnosis of stroke using DWI images in all
cases and statistical analysis after adjusting for multiple con-
founding variables. We found that circulating IL-6 and
hFABP levels showed an independent association with
stroke prognosis after adjusting for clinical covariates.
Moreover, the combination of these two markers showed a
significant improvement of discrimination and reclassifica-
tion for high and low risk of clinical outcome in stroke
patients. Other blood markers failed to show a significant
clinical value for the prediction of stroke outcome.
Previous studies demonstrated that IL-6 is one of the
predictors of poor outcome in stroke [16-20]. Our finding
of the strong association between IL-6 and poor stroke
outcome is consistent with those of several studies using
multiple blood markers in prospective stroke cohorts [4,5].
A systemic inflammatory response develops after brain
damage during the acute phase of ischemic stroke. IL-6 is
one of the most important mediators of the acute phase
response to inflammation. The precise mechanism of the
association between elevated IL-6 levels and poor clinical
outcome is unclear. IL-6 up-regulates the expression of
adhesion molecules, such as intercellular adhesion mole-
cule-1 (ICAM-1), selectins and integrins on endothelial
cells, leukocytes and platelets, during cerebral ischemia,
Table 4 Receiver operating characteristic (ROC) curve and in-sample reclassification analysis of the addition of each or
the combination of IL-6 and hFABP (natural log-transformed) to the baseline clinical model for stroke outcome
Discrimination Reclassification
AUC (95% CI) Pb NRI Pc IDI Pd
Baseline clinical modela 0.910 (0.858 to 0.948) - - -
+ logIL-6 0.931 (0.883 to 0.964) 0.075 0.09 0.036 0.03 0.024
+ loghFABP 0.926 (0.877 to 0.960) 0.110 0.07 0.232 0.02 0.032
+ logIL-6 + loghFABP 0.939 (0.893 to 0.970) 0.032 0.18 0.005 0.06 0.001
aModel with age and initial NIHSS score; bP-value for AUC using DeLong method with the baseline clinical model as a reference; cP-value for net classification
improvement with the baseline clinical model as a reference; dP-value for integrated discrimination improvement with the baseline clinical model as a reference.
AUC, area under curve; IDI, integrated discrimination improvement; log, natural log-transformed value; NRI, net reclassification improvement.
Figure 1 Receiver operating characteristic (ROC) curve of the
addition of the combination of logIL-6 and loghFABP to the
clinical baseline model.
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which leads to secondary neuronal damage [21]. IL-6 also
increases the levels of fibrinogen and von Willebrand fac-
tor, resulting in hypercoagulant status [22]. IL-6 expres-
sion is increased in the brain following ischemia, and
damaged neurons may contribute to increased IL-6 levels
[23]. Although the source of circulating IL-6 during the
acute phase of stroke is still unknown, the early increase
in IL-6 and its correlation with poor outcome support the
role of acute inflammation in the pathophysiology of
stroke.
Using a blood IL-6, we did not find any improvement
in the prognostic performance of the clinical model for
stroke outcome despite the close pathophysiological rela-
tionship between IL-6 and cerebral ischemia. Our results
are consistent with previous studies which showed that
IL-6 lacks clinical usefulness in the discrimination and
reclassification between favorable and poor outcome
groups of stroke patients [4,5]. In our data, the combined
use of IL-6 and hFABP significantly improved the discri-
minating ability of the clinical model poor stroke out-
come. The addition of IL-6 and hFABP significantly
reclassified patients at low- and high-risk for poor out-
come across the clinically relevant threshold. hFABP is a
small cytoplasmic protein (15 kDa) that is involved in
active fatty acid metabolism in the myocardium and neu-
ronal cell bodies in the central nervous system [24].
Plasma hFABP level is known to be a sensitive biomarker
of acute coronary ischemia [25,26]. In ischemic stroke,
plasma hFABP levels were found to be elevated in several
case-control studies [27-29]. Plasma hFABP levels six
hours after stroke were associated with early neurological
severity (NIHSS score at 10 days) and long-term outcome
(mRS at three months) [28,29]. The precise mechanism
of the association between blood hFABP and stroke out-
come is unclear. One plausible explanation is that hFABP
is released from the brain following cerebral ischemia.
Proteomic analysis showed that hFABP levels in cere-
brospinal fluid were elevated in deceased stroke patients
[27]. However, we did not find a significant correlation
between infarct volume and hFABP, indicating the extra-
cerebral origin of hFABP release following stroke. A sec-
ond explanation is that the elevation of blood hFABP
reflects acute cardiovascular dysfunction associated with
neuronal injury [30], which is associated with poor out-
come. A third explanation is that hFABP is elevated in
other conditions, such as heart failure [31], sepsis [32],
pulmonary embolism [33], and metabolic syndrome [34],
which may be an underlying substrate for poor stroke
outcome. Further studies are required to clarify the origin
of hFABP release during the acute phase of stroke and its
predictive value for stroke outcome.
Neuro-astroglial markers are candidate stroke biomar-
kers because they are hypothetically more specific to brain
injury than inflammatory and haemostatic markers.
Several case-control studies showed that blood levels of
S100B, NSE and GFAP are elevated in acute stroke, and
are associated with poor stroke outcome [7-9]. We evalu-
ated the blood profiling of several neuro-astroglial mar-
kers, including candidate neuronal markers (VSNL-1 and
Ngb) that have not been tested in human stroke patients
[35,36]. None of the tested markers, with the exception of
hFABP, reached statistical significance. The lack of an
association between blood levels and stroke outcome in
the present study is attributable to their slow release
kinetics from damaged tissue to peripheral blood (that is,
their peak plasma levels were reached at 48 to 72 hours
after stroke onset) [8,28].
The limitations of the present study should be
addressed. First, we did not perform serial measurements
of the blood markers. The inflammatory process and
release of neuro-astroglial proteins are prominent for sev-
eral days after a stroke. Therefore, the measurement of
blood markers within 24 hours after stroke onset weakens
the potential application. The aim of our study is to search
for panel markers within 24 hours of stroke onset for pre-
diction of stroke outcome, as prediction of stroke outcome
is required as soon as possible considering the high mor-
tality and morbidity of stroke. We also excluded patients
with their onset within six hours because most cases dur-
ing this time period need thrombolytic therapy, which
may confound the clinical outcome of cerebral infarction,
and because our experience has shown that most of the
tested biomarkers (especially neuro- and astroglial pro-
teins) are not elevated within six hours after symptom
onset. Second, it is unknown whether the elevation of
blood markers represents a consequence or a pre-morbid
status of stroke, as inflammatory and haemostatic markers
are elevated in non-cerebral conditions, such as systemic
infection, cancer or metabolic diseases. Further studies
that involve serial measurement of blood marker levels are
required to resolve this issue. Third, the sample size of our
study was small. Our results should be interpreted with
caution, and external validation is required to be general-
ized in clinical practice. Fourth, we could not examine the
candidate blood markers for prediction of stroke outcome
in the previous studies, including brain natriuretic peptide
(BNP or NT-proBNP) [4], midregional pro-atrial natriure-
tic peptide (MR-proANP) [37], lipoprotein-associated
phospholipase A2 (LpPlA2) [38], or copeptin [39]. Further
studies that expand the panel of blood markers screened
are required.
Conclusions
We found that blood IL-6 and hFABP levels are associated
with poor clinical outcome in patients with ischemic
stroke. Single markers did not enhance the discriminating
ability of the clinical predictors for stroke outcome. The
addition of the IL-6 and hFABP levels improved the
Park et al. Critical Care 2013, 17:R45
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prognostic performance of the clinical predictors for
stroke outcome. Further studies in a large-scale prospec-
tive cohort are required to determine whether these blood
proteins are clinically useful in routine clinical practice for
prediction of those at high-risk of a poor clinical outcome,
who need more intensive therapeutic strategies.
Key messages
• Combination of multiple blood markers that
involve different biological pathways may enhance
the predictability of clinical parameters for stroke
outcome.
• Blood IL-6 and hFABP levels were independently
associated with the functional outcome at three
months in patients with ischemic stroke.
• Combination of blood markers including IL-6 and
hFABP improved the predictive value of clinical pre-
dictors for stroke outcome.
Additional material
Additional file 1: Methods for individual blood markers.
Additional file 2: Reclassification table for favorable and poor
stroke outcome.
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